Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
VR

NASDAQ · VRDN

Viridian Therapeutics, Inc.

Healthcare · Biotechnology

$22.73

Down-$0.44 (-1.94%)

Updated Sep 11, 2026, 1:40 AM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.64B
P/E ratio
-7.73
Dividend yield
0.00%
52-week range
$13.18 – $30.42
Volume
1.58M
Avg. volume
1.41M

Price performance

VRDN price history

1M range · 19 trading sessions · Daily adjusted prices

VRDN closed at $22.73 after 19 trading sessions, up 3.37% for the selected period.

Last close
$22.73
Period change
+3.37%
Period low
$21.99
Period high
$24.80
Daily close
View OHLC price history
VRDN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$23.11$23.58$22.70$22.731.58M
Sep 8, 2026$22.38$23.835$22.2201$23.171.83M
Sep 4, 2026$22.62$23.03$22.62$22.92759.92K
Sep 3, 2026$23.08$23.28$22.57$22.961.19M
Sep 2, 2026$23.11$23.735$22.39$22.781.42M
Sep 1, 2026$23.02$23.34$22.885$23.03998.38K
Aug 31, 2026$22.94$23.27$22.62$23.161.05M
Aug 28, 2026$23.58$23.70$23.04$23.08778.88K
Aug 27, 2026$24.22$24.4664$23.75$23.88839.84K
Aug 26, 2026$24.16$24.455$23.92$24.26780.82K
Aug 25, 2026$24.30$24.80$24.08$24.18901.43K
Aug 24, 2026$24.35$24.39$24.00$24.021.13M
Aug 21, 2026$24.65$24.745$24.07$24.29906.3K
Aug 20, 2026$24.61$24.72$23.96$24.501.08M
Aug 19, 2026$24.52$24.86$23.80$24.801.83M
Aug 18, 2026$23.00$23.95$22.84$23.931.99M
Aug 17, 2026$21.92$23.29$21.869$23.091.89M
Aug 14, 2026$22.00$22.23$21.62$22.081.09M
Aug 13, 2026$22.70$22.86$21.89$21.991.77M

Latest VRDN news

The latest Smart Investors Daily articles mentioning VRDN.

Stock researchCompany · Overview

VRDN research

Overview

Company profile and research snapshot.

Company profile

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$41.57
Implied upside
—
Analysts
—
VRDN recent ratings
DateFirmRatingTarget
Aug 7, 2026RBC CapitalOutperform—
Aug 7, 2026Truist SecuritiesBuy—
Jun 30, 2026WedbushOutperform—
Jun 30, 2026Truist SecuritiesBuy—
Jun 30, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

WALTHAM, Mass., September 02, 2026--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 12:45pm ET.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By